Sarepta Therapeutics (SRPT) Gross Profit (2017 - 2026)

Sarepta Therapeutics' Gross Profit history runs 10 years deep, the most recent figure standing at $291.5 million for Q1 2026.

• In Q1 2026, Gross Profit rose 6990.1% year-over-year to $291.5 million; the TTM figure through Mar 2026 stood at $1.0 billion (down 14.22% YoY), while the FY2025 annual figure was $1.4 billion, down 14.17% from the prior year.
• Gross Profit was $291.5 million for Q1 2026 at Sarepta Therapeutics, up from $44.2 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $526.1 million in Q4 2024 to a low of -$11.9 million in Q2 2023.
• Historically, Gross Profit has averaged $236.0 million across 5 years, with a median of $248.6 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Gross Profit slumped 107.58% in 2022, then jumped 6990.1% in 2026.
• A 5-year view of Gross Profit shows it stood at $138.4 million in 2022, then jumped by 203.04% to $419.4 million in 2023, then grew by 25.46% to $526.1 million in 2024, then tumbled by 91.59% to $44.2 million in 2025, then jumped by 559.16% to $291.5 million in 2026.
• The last three Gross Profit figures came in at $291.5 million (Q1 2026), $44.2 million (Q4 2025), and $248.6 million (Q3 2025), per Business Quant data.